Table 1.
Post-vaccine (%) | Infection (%) | P | |
---|---|---|---|
Groups | |||
Pediatric | 37 (2.9) | 1256(97.1) | 0.0001* |
Adult | 250 (72.9) | 93 (27.1) | |
Time of clinical symptoms (days) | 8.73 ± 7.8 | 3.17 ± 2.8 | 0.06** |
Clinical manifestations | |||
GBS or cranial neuropathy | 125 (64.1) | 70 (35.9) | 0.0001* |
Seizures and status epilepticus | 23 (5.9) | 369 (94.1) | 0.0001* |
ADEM | 20 (71.4) | 8 (28.6) | 0.0001* |
Encephalitis-Encephalopathy | 41 (8.0) | 471 (92) | 0.0001* |
Stroke | 7 (36.8) | 12 (63.2) | 0.1* |
Myelitis | 3 (42.9) | 4 (57.1) | 0.1* |
Others | 68 (12.7) | 469 (87.3) | 0.0001* |
Clinical outcome | |||
Improvement | 287 (19.1) | 1218 (80.9) | 0.0001* |
Death | 0 | 60 (100) | |
Total of patients registering clinical outcome | 287 | 1349 |
GBS, Guillain-Barré syndrome; ADEM, acute disseminated encephalomyelitis. Statistically significant differences are in bold.
Chi-square test with Yates correction,
Student's t-test.